2007-076-201
Innovation Summary:
This invention provides a new class of opioid receptor binding compounds designed to ameliorate the peripheral side effects of therapeutic opiates (e.g., constipation, nausea, emesis, pruritis, dysphoria, urinary retention) without interfering with central analgesic activity. The compounds are derivatives of benzomorphans and morphinans in which the 8-hydroxyl (benzomorphans) or 3-hydroxyl (morphinans) group has been replaced with small, polar, neutral residues such as carboxamide, thiocarboxamide, hydroxyamidine, or formamide. These modifications improve oral bioavailability, reduce susceptibility to Phase II metabolism (e.g., glucuronidation and sulfonation), and extend half-life compared to existing opioids and antagonists. Substitution on the amide nitrogen with larger, less polar groups further tunes receptor affinity and selectivity. These compounds demonstrate excellent opioid receptor binding and potent peripheral antagonism, making them superior candidates for managing opioid-induced side effects at lower doses than current therapies (e.g., methylnaltrexone).
Challenges / Opportunities:
A major challenge in opioid pharmacology is the poor oral bioavailability and rapid clearance of traditional opioids and antagonists due to the presence of hydroxyl groups that undergo Phase II metabolism. This leads to short half-lives, high dosing requirements, and diminished therapeutic benefit. Additionally, while peripherally acting antagonists like methylnaltrexone can reduce opioid-induced constipation, their efficacy requires relatively high doses, which can limit tolerability and increase cost.
The present invention solves these problems by designing structural modifications that retain opioid receptor affinity while eliminating metabolic liabilities, thereby producing long-acting, orally bioavailable compounds with strong peripheral selectivity. This creates opportunities for next-generation adjunct therapies that allow patients to continue receiving effective pain relief from opioids while minimizing unwanted side effects. Beyond constipation management, these compounds can improve post-operative bowel function, reduce opioid-induced nausea, and alleviate other peripheral complications, expanding their clinical utility. With rising demand for safer opioid regimens, these compounds have high potential for pharmaceutical development, licensing, and commercialization.
Key Benefits:
✔ Reduced central nervous system side effects ✔ High peripheral receptor selectivity ✔ Potential for safer opioid therapies ✔ Versatile use in pain management and addiction treatment
Applications:
• Safer pain relief medications • Addiction treatment drugs • Post-operative recovery aids • Gastrointestinal side effect reduction
Keywords: Opioid receptor antagonist; benzomorphan derivatives; morphinan derivatives; carboxamide substitution; peripheral side effect reduction; oral bioavailability; Phase II metabolism resistance; opioid-induced constipation; methylnaltrexone alternatives
Intellectual Property: US Patent No. 8,263,807 and US Patent No. 8,563,572